uk
uk · page 18
- Policy & Regulation
UK drugs policy no longer fit for purpose, says leading criminologist
The Misuse of Drugs Act 1971 has been described as contributing to a “drug apartheid” resulting in a corrupt system discriminating along the lines of class, ethnicity and gender.
- Medical
Grow group: innovating cannabis medicines and improving access
Grow Group co-founder and CEO Ben Langley spoke about the company’s aims, cannabis innovation and its plans for expansion.
- CBD Market
Award-winning Vitality CBD acquired by Yooma Wellness
This is the first acquisition made since Yooma completed its dual-listing on the AQSE Growth Market in London.
- CBD Market
Cellular Goods sign agreement for launch of ingestible CBD products
The ingestible products will include a tincture, spray and capsules.
- Companies
Grow Group hits 100 per cent crowdfunding target in one hour
Grow Group is the first British medical cannabis startup ever to crowdfund.
- Your #1 Podcast on Cannabis News
Understanding the UK and European medical cannabis markets
On this episode of BofC Live, we connect with Dean Friday, CEO and Jonathan Nadler, Group Managing Director of LYPHE Group.
- Uncategorized
Tenacious Labs CEO discusses its acquisition of Press Pause
Tenacious Labs aims to bring Press Pause’s female-focused products to the UK to drive international growth.
- Medical
Second medical cannabis flower launched by Curaleaf for UK market
Curaleaf aims to improve access and affordability for UK patients with its new products.
- CBD Market
No longer up-in-smoke (only)
Earlier in the year, British American Tobacco (BAT), announced that they secured a nearly 20 percent interest in Canadian cannabis producer Organigram.
- CBD Market
Voyager establishes physical store for underserved UK CBD consumers
The physical store complements Voyager’s existing online sales and growing number of trade accounts.
- CBD Market
UK’s Quantum Farma to provide new cannabis treatments to Latin America
UK company Quantum Farma is working with FarmaUSA to launch two new cannabis treatments in the Latin American market.
- Pharmaceutical
Oxford Cannabinoid Technologies secures drug development agreements
The agreements follow its post-IPO review after its £16.5m fundraise and admission to the main market on LSE in May this year.
